J Gen Virol Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published as JGV in Press, 10.1099/vir.0.012831-0 on June 24, 2009 J Gen Virol 90 (2009), 2331-2341; DOI 10.1099/vir.0.012831-0

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary figure
Right arrow All Versions of this Article:
vir.0.012831-0v1
90/10/2331    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Katsumura, K. R.
Right arrow Articles by Takada, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katsumura, K. R.
Right arrow Articles by Takada, K.
Agricola
Right arrow Articles by Katsumura, K. R.
Right arrow Articles by Takada, K.

Quantitative evaluation of the role of Epstein–Barr virus immediate-early protein BZLF1 in B-cell transformation

Koichi Ricardo Katsumura1, Seiji Maruo1, Yi Wu1, Teru Kanda2,{dagger} and Kenzo Takada1

1 Department of Tumor Virology, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan
2 Research Center for Infection-Associated Cancer, Institute for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Japan

Correspondence
Kenzo Takada
kentaka{at}igm.hokudai.ac.jp

The Epstein–Barr virus (EBV) immediate-early transactivator BZLF1 plays a key role in switching EBV infection from the latent to the lytic form by stimulating the expression cascade of lytic genes; it also regulates the expression of several cellular genes. Recently, we reported that BZLF1 is expressed in primary human B cells early after EBV infection. To investigate whether this BZLF1 expression early after infection plays a role in the EBV-induced growth transformation of primary B cells, we generated BZLF1-knockout EBV and quantitatively evaluated its transforming ability compared with that of wild-type EBV. We found that the 50 % transforming dose of BZLF1-knockout EBV was quite similar to that of wild-type EBV. Established lymphoblastoid cell lines (LCLs) harbouring BZLF1-knockout EBV were indistinguishable from LCLs harbouring wild-type EBV in their pattern of latent gene expression and in their growth in vitro. Furthermore, the copy numbers of EBV episomes were very similar in the LCLs harbouring BZLF1-knockout EBV and in those harbouring wild-type EBV. These data indicate that disrupting BZLF1 expression in the context of the EBV genome, and the resultant inability to enter lytic replication, have little impact on the growth of LCLs and the steady-state copy number of EBV episomes in established LCLs.

{dagger}Present address: Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.

A supplementary figure showing a comparison of GFP-inducing titre and EBNA-inducing titre of the recombinant viruses is available with the online version of this paper.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 2009 by the Society for General Microbiology.